SB271046 is a selective antagonist of the 5-HT6 receptor, a type of serotonin receptor that is primarily expressed in the brain. In this article, we will delve into the chemical properties of SB271046, its health benefits, potential effects, mechanism of action, possible side effects, and dosing information.
The chemical name of SB271046 is (R)-3-(2-(2,3-dihydrobenzo[b][1,4]dioxin-5-yl)ethyl)-1H-indole. Its molecular formula is C21H21NO2O2 and formula weight is 335.40 g/mol. The CAS number of SB271046 is 209481-20-9.
Top Ten Keywords and Synonyms
SB271046 has shown potential benefits in treating cognitive impairment associated with various neurological disorders such as schizophrenia, depression, and Alzheimer's disease. It may also have applications in enhancing memory and cognition in healthy individuals.
SB271046 primarily acts as an antagonist of the 5-HT6 receptor, which is involved in regulating the release of neurotransmitters such as dopamine, serotonin, and acetylcholine. By blocking the 5-HT6 receptor, SB271046 can enhance the release of these neurotransmitters, which may improve cognitive function, mood, and memory.
The 5-HT6 receptor is a G-protein-coupled receptor that modulates the release of various neurotransmitters in the brain. SB271046 selectively blocks the binding of serotonin to the 5-HT6 receptor, thereby reducing its downstream signaling pathways. This ultimately enhances the release of other neurotransmitters and improves cognitive function and memory.
SB271046 has demonstrated a good safety profile in preclinical studies. However, there is limited information on its safety in humans, and further research is needed to determine its long-term safety and potential toxicities.
There is limited information on the side effects of SB271046 in humans. In animal studies, SB271046 has been shown to cause sedation and impair motor function, but these effects are generally mild and reversible.
SB271046 has been administered orally in preclinical studies at doses ranging from 0.1 to 30 mg/kg. The optimal dose and duration of treatment for various neurological disorders are unknown, and further research is needed to establish safe and effective dosing regimens.
SB271046 is a promising 5-HT6 receptor antagonist with potential therapeutic applications in cognitive impairment associated with various neurological disorders such as schizophrenia, depression, and Alzheimer's disease. Its mechanism of action involves enhancing the release of neurotransmitters such as dopamine, serotonin, and acetylcholine, which may improve cognitive function, mood, and memory. While it has demonstrated a good safety profile in preclinical studies, more research is needed to determine its long-term safety and potential side effects in humans. Nonetheless, SB271046 has great potential as a novel therapeutic agent in the treatment of various neurological disorders.